This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Pharmaceutical manufacturing Remove Product sample Related Topics
Food and Drug Administration Safety FDA Food Manufacturing Medicine Management Pharmaceutical Marketing More Related Topics >
article thumbnail

FDA releases analysis on drug product quality in 2022

European Pharmaceutical Review

JULY 3, 2023

Reflecting on five years of quality control for nitrosamine impurities Warning Letters In FY2022, the FDA issued 72 CGMP-related warning letters to pharmaceutical manufacturing sites. Most that received warning letters (68 percent) were FDF manufacturers of non-sterile, non-application products.

FDA 92
FDA Food and Drug Administration Manufacturing Product sample 92
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024